Differential impact of macrolide compounds in the selection of macrolide nonsusceptible Streptococcus pneumoniae

Therapy

Volumn 2, Issue 6, 2005, Pages 813-818

  Blondeau, Joseph M ^a  

^a ROYAL UNIVERSITY HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

AZITHROMYCIN; CLARITHROMYCIN; COTRIMOXAZOLE; ERYTHROMYCIN; JOSAMYCIN; MACROLIDE; PENICILLIN G; QUINOLONE DERIVATIVE; ROXITHROMYCIN;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ANTIMICROBIAL ACTIVITY; BACTERIAL STRAIN; BACTERIAL VIRULENCE; BACTERICIDAL ACTIVITY; BACTERIOSTASIS; BACTERIUM CULTURE; BACTERIUM ISOLATE; BACTERIUM ISOLATION; CLINICAL TRIAL; COLONY FORMING UNIT; DRUG BLOOD LEVEL; DRUG ELIMINATION; DRUG EXPOSURE; DRUG HALF LIFE; DRUG POTENCY; DRUG TISSUE LEVEL; EDITORIAL; HOSPITAL INFECTION; HUMAN; INCIDENCE; INFECTION SENSITIVITY; MINIMUM INHIBITORY CONCENTRATION; MOUTH FLORA; NONHUMAN; RISK FACTOR; STREPTOCOCCUS PNEUMONIA; STREPTOCOCCUS PNEUMONIAE; THROAT CULTURE;

EID: 28344437914     PISSN: 14750708     EISSN: 1744831X     Source Type: Journal    
DOI: 10.1586/14750708.2.6.813     Document Type: Editorial

References (30)

1. Blondeau JM, Tillotson GS. Antibiotic dosing: do we dose to cure the individual or do we treat the greater societal needs? Therapy 2, 511-516 (2005).
2. Blondeau JM, Hansen G, Metzler KL, Hedlin P. The role of PK/PD parameters to avoid selection and increase of resistance: mutant prevention concentration. J. Chemother. 16, 1-19 (2004).
3. Baquero F. Evolving resistance patterns of Streptococcus pneumoniae: a link with long-acting macrolide consumption? J. Chemother. 11, 35-43 (1999).
4. Blondeau JM, Metzler KL, Hedlin P, Hansen G, Drlica K. Comparison of the mutant prevention concentration of gatifloxacin, garenoxacin, gemifloxacin, levofloxacin and moxifloxacin against clinical isolates of Streptococcus pneumoniae collected prior to (1994-97) and after 1997 (1997-2003). Presented at: The 14th European Congress of Clinical Microbiology and Infectious Diseases. Prague, Czech Republic (2004).
5. Blondeau JM, Borsos S. Application of the resistance Prevention Concentration (RPC) & Minimal Inhibitory Concentration (MIC) of clinical isolates of Streprococcus pneumoniae (SP) aganinst macrolides. Presented at: The World Conference on Magic Bullets - to Celebrate Paul Ehrlich's 150th Birthday September 9-11 2004. Nurnberg, Germany (2004) (Abstract).
6. Zhanel GG, Palatnick L, Nichol KA, Bellyou T, Low DE, Hoban DJ. Antimicrobial resistance in respiratory tract Streptococcus pneumoniae isolates: results of the Canadian Respiratory Organism Susceptibility Study, 1997 to 2002. Antimicrob. Agents Chemother. 47, 1867-1874 (2003).
7. Bingen E, Lambert-Zechovsky N, Mariani-Kurkdjian P, et al. Bacterial counts in cerebrospinal fluid of children with meningitis. Eur. J. Clin. Microbiol. Infect. Dis. 9, 278-281. (1990).
8. Feldman W. Concentrations of bacteria in cerebrospinal fluid of patients with bacterial meningitis. J. Pediatr. 88, 549-552 (1976).
9. Mitchison DA. Drug resistance in mycobacteria. Br. Med. Bull. 50, 84-90 (1984).
10. Firsch AW, Tripp JT, Barrett Jr. CD, Pidgeon BE. Specific polysaccaride content of pneumoni lungs. J. Exp. Med. 76, 505-510 (1942).
11. Vanderkooi OG, Low DE, Green K, Powis JE, McGeer A. Predicting antimicrobial resistance in invasive pneumococcal infections. Clin. Infect. Dis. 40, 1288-1297 (2005).
12. Garcia-Rey C, Aguilar L, Baquero F, Casal J, Martin JE. Pharmacoepidemiological analysis of provincial differences between consumption of macrolides and rates of erythromycin resistance among Streptococcus pyogenes isolates in Spain. J. Clin. Microbiol. 40, 2959-2963 (2002).
13. Pihlajamaki M, Kotilainen P, Kaurila T, Klaukka T, Palva E, P. H. Macrolide-resistant Streptococcus pneumoniae and use of antimicrobial agents. Clin. Infect. Dis. 33, 483-488 (2001).
14. Granizo JJ, Aguilar L, Casal J, Garcia-Rey C, Dal Re R, Baquero F. Streptococcus pneumoniae resistance to erythromycin and penicillin in relation to macrolide and B-lactam consumption in Spain (1979-1997). J. Antimicrob. Chemother. 46, 767-773 (2000).
15. Reinert RR, Lahham AL, Lemperle M et al. Emergence of macrolide and penicillin resistance among invasive pneumococcal isolates in Germany. J. Antimicrob. Chemother. 49, 61-68 (2002).
16. Kastner U, Guggenbichler JP. Influence of macrolide antibiotics on promotion of resistance in the oral flora of children. Infection 5, 251-256 (2001).
17. Davidson RJ, Chan CCK, Doern GV, Zhanel GG. Macrolide-resistant Streptococcus pneumoniae in Canada: correlation with azithromycin use. Clin. Microbiol. Infect. 9, 240-241 (2003).
18. Doern GV. Antimicrobial use and the emergence of antimicrobial resistance with Streptococcus pneumoniae in the United States. Clin. Infect. Dis. 33(Suppl.), S187-S192. (2001).
19. Diekema DJ, Brueggemann AB, Doern GV. Antimicrobial-drug use and changes in resistance in Streptococcus pneumoniae. Emerg. Infect. Dis. 6, 552-556 (2000).
20. Leach AJ, Shelby-James TM, Mayo M et al. A prospective study of the impact of community-acquired azithromycin treatment of trachoma on carriage and resistance of Streptococcus pneumoniae. Clin. Infect. Dis. 24, 356-362 (1997).
21. Edelstein PH. Predicting the emergence of antimicrobial resistance (correspondence). Clin. Infect. Dis. 34, 1418 (2002).
22. Doern GV. Predicting the emergence of antimicrobial resistance (reply). Clin. Infect. Dis. 34, 1418-1420 (2002).
23. Ghaffar F, Muniz LS, Katz K et al. Effects of amoxicillin/clavulanate or azithromycin on nasopharyngeal carriage of Streptococcus pneumoniae and Haemophilus influenzae in children with acute otitis media. Clin. Infect. Dis. 31, 875-880 (2000).
24. Gray GC, Witucki PJ, Gould MT et al. Randomized placebo-controlled clinical trial of oral azithromycin prophylaxis against respiratory infections in a high-risk, young adult population. Clin. Infect. Dis. 33, 983-990 (2001).
25. Hyde TB, Gay K, Stephens DS et al. Macrolide resistance among invasive Streptococcus pneumoniae isolates. JAMA 286, 1857-1862 (2001).
26. Garcia-Rey C, Aguilar L, Baquero F et al. Importance of local variations in antibiotic consumption and differences in erythromycin and penicillin resistance in Streptococcus pneumoniae. J. Clin. Microbiol. 40, 159-164 (2002).
27. Patel KB, Xuan D, Tessier PR et al. Comparison of bronchopulmonary pharmacokinetics of clarithromycin and azithromycin. Antimicrob. Agents Chemother. 40, 2375-2379 (1996).
28. Conte Jr. JE, Golden J, Duncan S et al. Single dose intrapulmonary pharmacokinetics of azithromycin, clarithromycin, ciprofloxacin and cefuroxime in volunteer subjects. Antimicrob. Agents Chemother. 40, 1617-1622 (1996).
29. Rodvold KA, Gotfried M, Danziger LH, Servi R. Intrapulmonary steady-state concentrations of clarithromycin and azithromycin in healthy adult volunteers. Antimicrob. Agents Chemother. 41, 1399-1402 (1997).
30. Doern GV. How using a potent antibiotic reduces the risk of resistance. J. Respir. Dis. 35, S9-S14 (2004).